Hong Kong’s biotech investment ecosystem is booming after listing reforms
HKEX’s listing reforms launched in 2018 opened a new pathway for pre-revenue biotech companies to raise capital, fuelling an era of growth that has made Hong Kong the world’s second-largest fundraising biotech hub for the sector